Anuhar Chaturvedi

Mainz, RP, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.

mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.

Journal: Nature immunology
Published: October 01, 2025

Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6.

Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6.

Journal: Science translational medicine
Published: May 22, 2024

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.

Journal: Oncoimmunology
Published: October 20, 2023

A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.

A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.

Journal: Journal of medicinal chemistry
Published: November 02, 2021

Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite.

Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite.

Journal: Cancers
Published: March 10, 2021

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.

Journal: Blood advances
Published: January 25, 2021

A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.

A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.

Journal: Leukemia
Published: January 19, 2021

Rationalization of the activity Profile of Pyruvate Kinase Isozyme M2 (PKM2) Inhibitors using 3D QSAR.

Rationalization of the activity Profile of Pyruvate Kinase Isozyme M2 (PKM2) Inhibitors using 3D QSAR.

Journal: Current topics in medicinal chemistry
Published: December 30, 2020

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.

Journal: Annals of hematology
Published: March 10, 2020

IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis.

IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis.

Journal: Leukemia
Published: December 19, 2019

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.

Journal: Haematologica
Published: September 09, 2019

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.

Journal: Annals of hematology
Published: April 28, 2019
Showing 1-12 of 33

Last Updated: 09/26/2026